title: A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early-morning disability in Parkinson's disease. The U.K. Madopar CR Study Group.
abstract: In a double-blind, crossover study, 103 patients with Parkinson's disease and nocturnal and/or early-morning disabilities took a bedtime dose of either Madopar CR (controlled-release levodopa plus benserazide) or standard Madopar, in addition to their usual daytime levodopa regimen. The mean optimum dosages were as follows: Madopar CR, 2.4 125 mg capsules; standard Madopar, 2.2 125 mg capsules. Assessment by daily patient diary and the doctor's record showed that nocturnal and early-morning disability was reduced by both treatments compared with at the start of the study, the difference being statistically significant. Improvement occurred in a similar number of patients when taking Madopar CR or standard Madopar (nocturnal disability improved in 61% on Madopar CR, and 57% on standard Madopar: early-morning disability improved in 46% on Madopar CR, and 44% on standard Madopar) and the percentage of patients wishing to continue on each treatment was also similar (64% on Madopar CR, and 55% on standard Madopar). However, in two-thirds of all cases, both doctor and patient felt that there was a difference between the treatments. Both Madopar CR and standard Madopar were of benefit to patients with nocturnal disability and, to a lesser extent, to those with early-morning problems. However, some patients responded better to Madopar CR and some to standard Madopar.
mesh_terms: D000203:Activities of Daily Living; D000368:Aged; D001545:Benserazide / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002940:Circadian Rhythm / Q000187:drug effects; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004338:Drug Combinations / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage*; D007980:Levodopa / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D003692:Delayed-Action Preparations; D004338:Drug Combinations; D006834:Hydrazines; C005177:benserazide, levodopa drug combination; D007980:Levodopa; D001545:Benserazide